The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.
Ongoing clinical trials for diabetic gastroparesis: No longer recruiting
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects with Gastroparesis
|Description of study:||
The purpose of this research study is to test an experimental drug called GSK962040. The researchers want to see if the drug can improve the time of stomach emptying (food and drink emptying from the stomach) in people with diabetes. These people also have a stomach condition called gastroparesis, which means partial paralysis of the stomach. We also want to see if the drug will cause side effects.